Generic drugmakers face pricing pressure, but companies like TEVA, SDZNY and RDY are betting on complex generics and biosimilars to protect growth.

Aspen Pharmacare, a South African drugmaker, plans to enter the Canadian market with a generic version of Novo Nordisk’s blockbuster diabetes and weight-loss drug Ozempic by the third quarter of 2026.

Use ChatGPT to improve your LinkedIn profile today with three practical prompts to sharpen your headline, About section, and ...

Sedona inpatient program educates on iloperidone side effects, anticholinergic burden, and holistic alternatives for ...

— Adrian García, CEO of Saya Bio. MEXICO CITY, MEXICO, January 26, 2026 /EINPresswire.com/ — Saya Biologics (Saya Bio), a Mexican biopharmaceutical company ...

GLP-1 therapies are a cornerstone for the management of type 2 diabetes, supporting glycemic control and improving patients’ quality of life. We are committed to expanding access to therapies that ...

Chinese drugmaker Jiuyuan Genetic Biopharmaceutical (HKEX: 2566) has applied for approval to market its biosimilar version of ...

Mounjaro, launched in India in March last year, has seen strong uptake, reflecting a broader shift in how obesity is being treated.

March 6 (Reuters) - The global weight-loss drug market is entering a new phase, driven by the arrival of oral options, looming generic rivals and falling U.S. prices for blockbuster treatments from ...